Protocol Ledger

NCT06317649 · Phase II · RECRUITING

Venetoclax and HMA Treatment of Older and Unfit Adults With FLT3 Mutated Acute Myeloid Leukemia (AML) (A MyeloMATCH Treatment Trial)

Interventional Phase II clinical trial protocol NCT06317649 sponsored by National Cancer Institute (NCI) in Oncology and Hematology, reconciled from NIH NLM ClinicalTrials.gov REST API v2.

Start Date: 2024-09-27 Enrollment: 147 participants (ESTIMATED) Federal Source: clinicaltrials.gov/study/NCT06317649
Track in Studio / Generate Client Brief ->
Registered Enrollment vs Phase II/III Median (145 pts)147 participants (ESTIMATED)
Disclosed U.S. Hospital Campuses vs Median (6 sites)4 sites

Reconciled ClinicalTrials.gov v2 Protocol Specification

Structured Registry Fields for NCT06317649
Protocol FieldVerified Registry Value
NCT IdentifierNCT06317649
Consolidated Lead SponsorNational Cancer Institute (NCI)
Therapeutic Condition CohortOncology and Hematology
Clinical Trial PhasePhase II
Overall Recruitment StatusRECRUITING
Registered Enrollment147 participants (ESTIMATED)
Registered Start Date2024-09-27
WhyStopped ClassificationNot Stopped

Named U.S. Hospital Clinical Research Sites

Search related sites and sponsors in the Interactive Directory, explore Oncology and Hematology Benchmarks, or read the Healthcare Price & Patent Cliff Crosswalk.

Need custom healthcare data pipelines, identifier crosswalks, or workflow automation? Talk to Meru AI